Takeda: Esophagitis trials

The registry lists 24 Esophagitis studies with Takeda as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 2Phase 2 5Phase 3 12Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)TerminatedNCT03245840Phase 3Results posted
• Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"CompletedNCT03214952Results posted
• Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"CompletedNCT03214081Results posted
• Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory EvaluationCompletedNCT03116841Phase 4Results posted
• Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive EsophagitisTerminatedNCT02873702Phase 3Results posted
• Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term SafetyCompletedNCT02679508Phase 4Results posted
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is AchievedCompletedNCT02605837Phase 3Results posted
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive EsophagitisCompletedNCT02388737Phase 3Results posted
• Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive EsophagitisCompletedNCT02388724Phase 3Results posted
• Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating TabletsCompletedNCT02096458Phase 1Results posted
• Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in AdolescentsCompletedNCT01642615Phase 2Results posted
• OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label ExtensionCompletedNCT01642212Phase 2Results posted
• Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic EsophagitisCompletedNCT00762073Phase 2Results posted
• Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive EsophagitisCompletedNCT00321737Phase 3Results posted
• Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive EsophagitisCompletedNCT00255164Phase 3Results posted
• Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisCompletedNCT00251719Phase 3Results posted
• Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisCompletedNCT00251693Phase 3Results posted
• A Study on Vonoprazan in the Real-world Clinical Practice in ChinaCompletedNCT04501627
• TAK-438 - Safety, Blood Levels & Effects of Repeated DosesCompletedNCT02141711Phase 1
• A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive EsophagitisCompletedNCT01630746Phase 3
• Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive EsophagitisCompletedNCT01459367Phase 3
• Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive EsophagitisCompletedNCT01452776Phase 3
• Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive EsophagitisCompletedNCT00471094Phase 2
• Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive EsophagitisCompletedNCT00175045Phase 2